Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein(a) levels by more than 90% for at least six months with a single injection in a phase 2 trial, reinforcing its ...

Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ahead ...

It’s a Sunday morning at the Magic 105.5 WMGH radio station, and Joe “Polka Joe” Manjack is fielding a string of song requests. There’s one for a Lansford woman celebrating a birthday, and another ...